Q-omics provides the consensus-scored PINX1 profile across patient tissues and cancer cell-line models. PINX1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PINX1 is differentially expressed in 14, with the highest sampling consensus in STAD. Additionally, PINX1 RNA expression shows 17,014 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, STAD, and ACC as cancer lineages where PINX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PINX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PINX1 survival associations across molecular data types. PINX1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PINX1 RNA expression–survival associations across cancer types. High PINX1 expression shows unfavorable associations in MESO, BLCA, KICH, LGG and UCS, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PINX1 RNA expression.
This table summarizes PINX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in STAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PINX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PINX1 shows lower tumor expression in THCA and higher tumor expression in STAD, LIHC, UCEC, COAD and CHOL. The STAD box plot shows higher PINX1 RNA expression in tumor versus normal tissue (log2 FC = +0.989, t-test p < 0.001).
This table shows molecular features associated with PINX1 in patient tissues and cancer cell lines. In patient samples, PINX1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PINX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
